Results 81 to 90 of about 4,990 (167)

Development of Optimized Exatecan-Based Immunoconjugates with Potent Antitumor Efficacy in HER2-Positive Breast Cancer. [PDF]

J Med Chem
Auvert E, Douez E, Jolivet L, Witkowski T, Jallas AC, Boursin F, Molnar I, Colas C, Wittmann SV, Auriol M, Chezal JM, Aubrey N, Allard-Vannier E, Maisonial-Besset A, Joubert N, Denevault-Sabourin C.   +15 more
europepmc   +1 more source

Harnessing Fc-Directed Bioconjugation for the Synthesis of Site-Specifically Modified Radioimmunoconjugates. [PDF]

Bioconjug Chem
Grimaldi C, Sebastiano J, Kao WM, Strugala E, McGlone SA, Watanabe T, Aoki T, Fujii T, Zeglis BM.   +8 more
europepmc   +1 more source

Cell death mechanisms induced by gold nano-immunoconjugates-mediated photodynamic therapy against human oesophageal cancer stem cells. [PDF]

Front Immunol
Didamson OC, Chandran R, Abrahamse H.
europepmc   +1 more source

Hepatocellular Carcinoma and Antibody Drug Conjugates: A Systematic Review. [PDF]

Cureus
Maddukuri S, Haddad RR, Battula NS, Chay T, Patel T, Dumaru N, Mohammed L.   +6 more
europepmc   +1 more source

It's a match: use of the radionuclide theranostic pair ¹³³La/²²⁵Ac for the radiopharmacological characterization of EGFR-targeted single-domain antibodies. [PDF]

EJNMMI Radiopharm Chem
Trommer J, Ullrich M, Reissig F, Brühlmann SA, Nitt-Weber AK, Novy Z, Hajduova K, Kurfurstova D, Hendrychova R, Bouchal J, Petrik M, Neuber C, Sihver W, Stadlbauer S, Pietzsch J, Kreller M, Kopka K, Mamat C, Zarschler K.   +18 more
europepmc   +1 more source

J3ExoA: A Novel Anti-HIV Immunotoxin Fusion of Anti-Gp120 J3VHH and PE38 Fragment of <i>Pseudomonas</i> Exotoxin A. [PDF]

Pharmaceuticals (Basel)
Pincus SH, Luo K, Peters T, Gordy JT, Cole FM, Klug G, Ober K, Marcotte TK, Markham RB.   +8 more
europepmc   +1 more source

Complete response following trastuzumab-deruxtecan in a man with HER2-overexpressing metastatic, poorly differentiated scrotal carcinoma. [PDF]

Oncologist
Hofstad M, Zheng J, Tachibana I, Zhang T.   +3 more
europepmc   +1 more source

Pharmacokinetic Optimization of Radiocopper-Based Theranostic Pretargeting. [PDF]

Mol Pharm
Cornejo MA, Samuels ZV, Dehlavi G, Carter L, Kao WM, Strugala E, Zeglis BM.   +6 more
europepmc   +1 more source

In Vitro and In Vivo Comparison of Random versus Site-Specific Conjugation of Bifunctional Chelating Agents to the CD33-Binding Antibody for Use in Alpha- and Beta-Radioimmunotherapy. [PDF]

ACS Omega
Allen KJH, Frank C, Jiao R, Malo ME, Bello M, De Nardo L, Meléndez-Alafort L, Dadachova E.   +7 more
europepmc   +1 more source

Beyond the hype: Antibody-Drug Conjugates are advancing faster than our clinical strategy. [PDF]

PLoS Med
Notini G, Bianchini G, Pérez-García JM, Cortés J.   +3 more
europepmc   +1 more source